Trimethylamine N-oxide, a gut microbiota-dependent metabolite in Chronic Hepatitis B

Esra Paydaş Hataysal; Muslu Kazım Körez; Turan Aslan; Fatma Şengül Bağ; Hifa Gülru Çağlar; Alev Kural; Hüsamettin Vatansev

Makale detayları

Trimethylamine N-oxide, a gut microbiota-dependent metabolite in Chronic Hepatitis B

Yazarlar:

Esra Paydaş Hataysal | Muslu Kazım Körez | Turan Aslan | Fatma Şengül Bağ | Hifa Gülru Çağlar | Alev Kural | Hüsamettin Vatansev

Yayıncı:

Selcuk University

Ana Başlıklar:

Gastroenteroloji ve Hepatoloji | Klinik Kimya

Dergi:

Genel Tıp Dergisi Vol.34 Issue 6, pp.853-860

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001333468

pISSN:

2602-3741

Anahtar kelimeler:

Özet:

 Background: Trimethylamine N-oxide TMAO, a gut microbiota metabolite is produced in the liver from dietary precursors such as choline, betaine, and L-carnitine. TMAO has been linked to inflammatory processes and oxidative stress, both of which are critical factors in the progression of hepatitis. This article aims to examine the impact of TMAO on Chronic hepatitis B CHB. Materials and Methods: The study included 41 treatment-naïve CHB patients with HBV DNA levels above 2000 IUmL, as well as 46 age and gender-matched controls. Serum TMAO levels were measured using Liquid Chromatography-Tandem Mass Spectrometry LCMSMS. All statistical analysis was performed with R version 4.2.1. Results: Patients with CHB have a more significant increase in serum level of TMAO than healthy controls 1860 IQR, 808  2720 vs. 552.5 IQR, 252  876.5, p0.001. Serum ALT and AST were higher in patients with CHB p0.001 and p0.001. TMAO levels were positively correlated with ALT and AST levels r0.466, p0.001; r0.376, p0.001 and had predictive power for CHB with an area under curve of 0.808. Conclusions: Our results indicate that there is a link between TMAO, a gut microbiota-dependent metabolite, and CHB disease. Since TMAO is synthesized mainly in the liver, its raised levels may be associated with liver-related diseases.

 Background: Trimethylamine N-oxide TMAO, a gut microbiota metabolite is produced in the liver from dietary precursors such as choline, betaine, and L-carnitine. TMAO has been linked to inflammatory processes and oxidative stress, both of which are critical factors in the progression of hepatitis. This article aims to examine the impact of TMAO on Chronic hepatitis B CHB. Materials and Methods: The study included 41 treatment-naïve CHB patients with HBV DNA levels above 2000 IUmL, as well as 46 age and gender-matched controls. Serum TMAO levels were measured using Liquid Chromatography-Tandem Mass Spectrometry LCMSMS. All statistical analysis was performed with R version 4.2.1. Results: Patients with CHB have a more significant increase in serum level of TMAO than healthy controls 1860 IQR, 808  2720 vs. 552.5 IQR, 252  876.5, p0.001. Serum ALT and AST were higher in patients with CHB p0.001 and p0.001. TMAO levels were positively correlated with ALT and AST levels r0.466, p0.001; r0.376, p0.001 and had predictive power for CHB with an area under curve of 0.808. Conclusions: Our results indicate that there is a link between TMAO, a gut microbiota-dependent metabolite, and CHB disease. Since TMAO is synthesized mainly in the liver, its raised levels may be associated with liver-related diseases.

 Background: Trimethylamine N-oxide TMAO, a gut microbiota metabolite is produced in the liver from dietary precursors such as choline, betaine, and L-carnitine. TMAO has been linked to inflammatory processes and oxidative stress, both of which are critical factors in the progression of hepatitis. This article aims to examine the impact of TMAO on Chronic hepatitis B CHB. Materials and Methods: The study included 41 treatment-naïve CHB patients with HBV DNA levels above 2000 IUmL, as well as 46 age and gender-matched controls. Serum TMAO levels were measured using Liquid Chromatography-Tandem Mass Spectrometry LCMSMS. All statistical analysis was performed with R version 4.2.1. Results: Patients with CHB have a more significant increase in serum level of TMAO than healthy controls 1860 IQR, 808  2720 vs. 552.5 IQR, 252  876.5, p0.001. Serum ALT and AST were higher in patients with CHB p0.001 and p0.001. TMAO levels were positively correlated with ALT and AST levels r0.466, p0.001; r0.376, p0.001 and had predictive power for CHB with an area under curve of 0.808. Conclusions: Our results indicate that there is a link between TMAO, a gut microbiota-dependent metabolite, and CHB disease. Since TMAO is synthesized mainly in the liver, its raised levels may be associated with liver-related diseases.

 Özet Giriş: Bağırsak mikrobiyota metaboliti olan Trimetilamin-N-oksit TMAO, kolin, betain ve L-karnitin gibi besin kaynaklarından karaciğerde üretilir. TMAO, hepatit ilerlemesinde kritik faktörler olan inflamatuar süreçler ve oksidatif stres ile ilişkilendirilmiştir. Bu çalışma, TMAOnun Kronik Hepatit B KHB üzerindeki etkisini incelemeyi amaçlamaktadır. Gereç ve Yöntemler: Çalışmaya, HBV DNA düzeyleri 2000 IUmLnin üzerinde olan 41 tedavi-naif KHB hastası ve yaş ve cinsiyet açısından eşleştirilmiş 46 kontrol grubu dahil edilmiştir. Serum TMAO seviyeleri, Sıvı Kromatografi-Tandem Kütle Spektrometrisi LCMSMS kullanılarak ölçülmüştür. Tüm istatistiksel analizler R versiyon 4.2.1 ile gerçekleştirilmiştir. Bulgular: KHB hastalarında serum TMAO düzeyleri, sağlıklı kontrollere göre anlamlı derecede daha yüksektir 1860 IQR, 808  2720 vs. 552.5 IQR, 252  876.5, p0.001. Serum ALT ve AST düzeyleri KHB hastalarında daha yüksekti p0.001 ve p0.001. TMAO düzeyleri, ALT ve AST seviyeleri ile pozitif korelasyon göstermiştir r0.466, p0.001; r0.376, p0.001 ve KHB tanısı için eğri altındaki alan 0.808di. Tartışma: Sonuçlarımız, bağırsak mikrobiyota bağımlı bir metabolit olan TMAO ile KHB hastalığı arasında bir bağlantı olduğunu göstermektedir. TMAO esas olarak karaciğerde sentezlendiğinden, artmış seviyeleri karaciğer hastalıklarıyla ilişkili olabilir.

Makale detayları

Trimethylamine N-oxide, a gut microbiota-dependent metabolite in Chronic Hepatitis B

Yazarlar:

Esra Paydaş Hataysal | Muslu Kazım Körez | Turan Aslan | Fatma Şengül Bağ | Hifa Gülru Çağlar | Alev Kural | Hüsamettin Vatansev

Yayıncı:

Selcuk University

Ana Başlıklar:

Gastroenteroloji ve Hepatoloji | Klinik Kimya

Dergi:

Genel Tıp Dergisi Vol.34 Issue 6, pp.853-860

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001333468

pISSN:

2602-3741

TMAO

LC/MS/MS

HBV

microbiotaTMAO

mikrobiota

HBV

LC/MS/MS

Sayı

Makale detayları

Yazarlar: Esra Paydaş Hataysal | Muslu Kazım Körez | Turan Aslan | Fatma Şengül Bağ | Hifa Gülru Çağlar | Alev Kural | Hüsamettin Vatansev

Yayıncı: Selcuk University

Ana Başlıklar: Gastroenteroloji ve Hepatoloji | Klinik Kimya

Dergi: Genel Tıp Dergisi Vol.34 Issue 6, pp.853-860

Belge Tipi: Makale

Yayın Tarihi: 12/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001333468

pISSN: 2602-3741

Sayı

Yazarlar:

Esra Paydaş Hataysal | Muslu Kazım Körez | Turan Aslan | Fatma Şengül Bağ | Hifa Gülru Çağlar | Alev Kural | Hüsamettin Vatansev

Yayıncı:

Selcuk University

Ana Başlıklar:

Gastroenteroloji ve Hepatoloji | Klinik Kimya

Dergi:

Genel Tıp Dergisi Vol.34 Issue 6, pp.853-860

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001333468

pISSN:

2602-3741